The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI)
A randomized trial
Marc Cohen, MD, FACC*,*,
Gian Franco Gensini, MD ,
Frans Maritz, MD ,
Enrique P. Gurfinkel, MD, PhD, FACC ,
Kurt Huber, MD, FACC||,
Ari Timerman, MD, PhD¶,
Maria Krzeminska-Pakula, MD#,
Nicolas Danchin, MD, FACC**,
Harvey D. White, DSc,
Jose Santopinto, MD, FACC,
Frederique Bigonzi, MD,
Carole Hecquet, MS,
Luc Vittori, MS TETAMI Investigators
* Newark Beth Israel Medical Center, Newark, New Jersey, USA
University of Florence, Florence, Italy
Karl Bremer Hospital, Bellville, South Africa
Favaloro Foundation, Buenos Aires, Argentina
|| University Clinic for Internal Medicine, Vienna, Austria
¶ Dante Pazzanese Institute of Cardiology, São Paulo, Brazil
# Medical University Lodz, Lodz, Poland
** Georges Pompidou Hospital, Paris, France
Green Lane Hospital, Auckland, New Zealand
Leonidas Lucero Municipal Hospital, Bahia Blanca, Argentina
Aventis Pharmaceuticals, Paris, France
View larger version (17K):
[in a new window]
|
Figure 1 Disposition of patients. UFH = unfractionated heparin.
|
|
View larger version (18K):
[in a new window]
|
Figure 2 Time to first event (death or adjudicated MI or adjudicated recurrent angina) at 30 days (enoxaparin vs. unfractionated heparin [UFH]) (intention-to-treat population, N = 1,224). Censor: marks point at which patients were withdrawn from study without further 30-day follow-up data.
|
|
|
